Faculty Opinions recommendation of Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Yearbook of Medicine ◽

10.1016/j.ymed.2011.09.006 ◽

2011 ◽

Vol 2011 ◽

pp. 18-19

Author(s):

R.S. Panush

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(10)61354-2 ◽

2011 ◽

Vol 377 (9767) ◽

pp. 721-731 ◽

Cited By ~ 1023

Author(s):

Sandra V Navarra ◽

Renato M Guzmán ◽

Alberto E Gallacher ◽

Stephen Hall ◽

Roger A Levy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Case Medical Research ◽

10.31525/ct1-nct04058028 ◽

2019 ◽

Author(s):

Keyword(s):

Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus

Faculty Opinions recommendation of Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737043169.793576809 ◽

2020 ◽

Author(s):

Tak Mao Chan ◽

Susan Yung

Keyword(s):

Lupus Erythematosus ◽

Type I Interferon ◽

Type I ◽

Systemic Lupus ◽

Phase 3 ◽

Randomised Controlled

EMBRACE: Phase 3/4, Randomized, 52‐Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41900 ◽

2021 ◽

Author(s):

Ellen Ginzler ◽

Luiz Sergio Guedes Barbosa ◽

David D’Cruz ◽

Richard Furie ◽

Kathleen Maksimowicz‐McKinnon ◽

...

Keyword(s):

Lupus Erythematosus ◽

African Ancestry ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3 ◽

Black African

OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials: Table 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1195 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 141.1-141 ◽

Cited By ~ 6

Author(s):

D. Isenberg ◽

J. Merrill ◽

R. Hoffman ◽

M. Linnik ◽

M. Morgan-Cox ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Phase 3

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo

O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials

10.1136/lupus-2020-eurolupus.36 ◽

2020 ◽

Author(s):

Eric F Morand ◽

Richard Furie ◽

Yoshiya Tanaka ◽

Rubana N Kalyani ◽

Gabriel Abreu ◽

...

Keyword(s):

Lupus Erythematosus ◽

Subgroup Analysis ◽

Systemic Lupus ◽

Phase 3 ◽

Patient Subgroup

FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/annrheumdis-2018-eular.1734 ◽

2018 ◽

Author(s):

R. van Vollenhoven ◽

B.H. Hahn ◽

G.C. Tsokos ◽

C. Wagner ◽

P. Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Systemic Lupus

S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

10.1136/lupus-2018-abstract.45 ◽

2018 ◽

Cited By ~ 1

Author(s):

R van Vollenhoven ◽

B Hahn ◽

G Tsokos ◽

C Wagner ◽

P Lipsky ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Interleukin 12 ◽

Phase 2 ◽

Efficacy And Safety ◽

Systemic Lupus